Acceso usuarios
China
Objetivo: la colitis ulcerosa (CU) es una enfermedad inflamatoria intestinal crónica de etiología inespecífica. La identificación de biomarcadores no invasivos que reflejen la actividad inflamatoria y predigan la respuesta terapéutica representa una necesidad clínica prioritaria. Este estudio tuvo como objetivo evaluar la utilidad del índice de grasa visceral de China (China Visceral Adiposity Index, CVAI) para determinar la actividad clínico-endoscópica de la CU y predecir la respuesta al tratamiento con vedolizumab.
Métodos: estudio retrospectivo que incluyó pacientes con CU (enero 2021-diciembre 2023) y controles sanos emparejados. La actividad clínica se evaluó mediante la puntuación Mayo modificada, y la respuesta terapéutica mediante el índice PRO2. La gravedad endoscópica se clasificó según la puntuación Mayo endoscópica (Mayo Endoscopic Score, MES). Se realizaron análisis ROC para comparar la capacidad discriminativa del CVAI entre grupos.
Resultados: los pacientes con CU (n = 82) presentaron valores de CVAI significativamente superiores a los controles (n = 72) (55,93 ± 25,14 vs.
36,34 ± 19,82; p < 0,001). El análisis ROC demostró que el CVAI mostró la mayor capacidad discriminativa (AUC = 0,720; IC 95 %: 0,65- 0,79). Se observó una correlación positiva entre el CVAI y las puntuaciones clínicas (r = 0,58; p < 0,01) y endoscópicas (r = 0,62; p < 0,01).
Los respondedores a vedolizumab presentaron valores basales de CVAI significativamente inferiores a los no respondedores (54,14 ± 15,45 vs.
72,84 ± 21,44; p = 0,002), mostrando el CVAI una capacidad predictiva moderada (AUC = 0,789; IC 95 %: 0,68-0,89).
Conclusión: el CVAI constituye un biomarcador prometedor para evaluar la actividad clínico-endos
Objective: ulcerative colitis (UC) is characterized by chronic nonspecifi c infl ammation of the intestinal tract. The identifi cation of non-invasive biomarkers that can refl ect intestinal infl ammation and predict therapeutic response is vital. This study aimed to assess the predictive value of the Chinese Visceral Adiposity Index (CVAI) for the assessment of both disease activity and response to vedolizumab therapy.
Methods: this retrospective study analyzed clinical data from patients with UC between January 2021 and December 2023. Healthy individuals were recruited as controls. Disease activity was evaluated using the modifi ed Mayo score, while clinical response was assessed using patient-reported outcomes (PRO2). Mayo Endoscopic Score (MES) was used for the grading of mucosal lesions. Receiver operating characteristic (ROC) curves were used to assess the ability of various indices to differentiate between patients with UC and healthy controls.
Results: patients with UC (n = 82) had signifi cantly higher CVAIs compared to healthy controls (n = 72) (36.34 ± 19.82 vs. 55.93 ± 25.14, p < 0.001). ROC analysis indicated that CVAI was the most effective predictive factor in distinguishing between patients with UC and healthy controls, with the highest area under the curve (AUC = 0.720). The CVAI was signifi cantly correlated with clinical activity and endoscopic scores in patients with UC, while patients who responded to vedolizumab had lower pre-treatment CVAIs compared to non-responders (54.14 ± 15.45 vs.
72.84 ± 21.44, p = 0.002). A low pre-treatment CVAI score was also effective in predicting the response to vedolizumab (AUC = 0.789).
Conclusion: the CVAI may be a valuable marker for assessing disease activity in UC and has the potential to predict the response to vedolizumab therapy
